Literature DB >> 28352489

Nonmotor Symptoms of Parkinson's Disease.

Shey-Lin Wu1, Rajka M Liscic2, SangYun Kim3, Sandro Sorbi4, Yuan-Han Yang5.   

Abstract

Entities:  

Year:  2017        PMID: 28352489      PMCID: PMC5352894          DOI: 10.1155/2017/4382518

Source DB:  PubMed          Journal:  Parkinsons Dis        ISSN: 2042-0080


× No keyword cloud information.
The classical clinical features of the Parkinson's disease (PD) are the motor disorders, in which parkinsonism is defined by the presence of bradykinesia plus at least one additional motor sign, rest tremor, rigidity, or impaired postural reflexes, the well-known clinical criteria [1]. However in the recent decades, scientists and physicians have received a lot of attention of the relevance and frequency of nonmotor symptoms (NMS) independently or dependently along with the motor symptoms [2, 3]. In PD, in general, in its different stages of disease it could be found that overall 98.6% of the PD patients have reported the presence of one or several NMS [4]. Those reported NMS might include olfactory dysfunction, neuropsychiatric manifestations as depression or cognitive impairments, sleep disorders as rapid eye movement behavior disorder, autonomic dysfunctions as gastrointestinal disorders, postural hypotension or urinary disorders, and fatigue pain. Among NMS, cognitive impairment is one of the most common and significant aspects of PD. The cognitive deficits such as executive deficit or visuospatial disturbances could seriously affect the quality of life, reduce life expectancy, prolong the duration of hospitalization, or therefore increase burdens of caregiver [5, 6]. The pathophysiology of cognitive deficits in PD is complex perhaps due to its complexity and variability from patient to patient. Furthermore, the treatment of cognitive impairment including pharmacotherapy and nonpharmacotherapy (e.g., cognitive training) is still with the limited evidence [7, 8]. Gastrointestinal dysfunction might occur at all stages of PD, often preceding the onset of central motor symptom. Evidence for abnormal α-synuclein throughout the enteric nervous system is growing [9]. Different gastrointestinal symptoms, such as dental problem, drooling, dysphagia, gastroparesis, gastroesophageal reflux, constipation, difficult defecation, or loss of weight, are frequent events in all the stages of Parkinson's disease. The treatment of these symptoms is still variable and inconclusive. In addition to pharmacotherapy, deep brain stimulation (DBS) is a powerful surgical treatment for many aspects of Parkinson disease but lacks consensus inasmuch as the impact of the DBS procedure on executive brain functions [10]. People with PD may experience felt stigma, such as shame, embarrassment, and disgrace, and enacted stigma when encountering responses of others, such as staring, questioning, and avoiding, to their visible features of movement and communication difficulties [11]. The qualitative research may allow a better understanding of a subjective symptom such as stigma in parkinsonian patients from an intercultural and a social point of view. In order to reach such purposes, this special issue will mainly focus on nonmotor symptoms of PD with its content including above-mentioned topics. We sincerely hope that this special issue will provide interesting new data as well as comprehensive up-to-date reviews for all readers.
  11 in total

1.  Toward a redefinition of Parkinson's disease.

Authors:  Matthew B Stern; Anthony Lang; Werner Poewe
Journal:  Mov Disord       Date:  2012-01       Impact factor: 10.338

2.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

Authors:  Andrew J Hughes; Susan E Daniel; Yoav Ben-Shlomo; Andrew J Lees
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

3.  A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data.

Authors:  C E Morrison; J C Borod; M F Brin; S A Raskin; I M Germano; D J Weisz; C W Olanow
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  2000-07

4.  What contributes to quality of life in patients with Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

5.  Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.

Authors:  Eugenia Mamikonyan; Sharon X Xie; Emilie Melvin; Daniel Weintraub
Journal:  Mov Disord       Date:  2015-04-25       Impact factor: 10.338

6.  Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI).

Authors:  Deepa Rao; Seung W Choi; David Victorson; Rita Bode; Amy Peterman; Allen Heinemann; David Cella
Journal:  Qual Life Res       Date:  2009-04-25       Impact factor: 4.147

7.  Dementia and survival in Parkinson disease: a 12-year population study.

Authors:  T C Buter; A van den Hout; F E Matthews; J P Larsen; C Brayne; D Aarsland
Journal:  Neurology       Date:  2008-03-25       Impact factor: 9.910

8.  Effects of cognitive training in Parkinson's disease: a randomized controlled trial.

Authors:  Annette Petrelli; Stephanie Kaesberg; Michael T Barbe; Lars Timmermann; Gereon R Fink; Josef Kessler; Elke Kalbe
Journal:  Parkinsonism Relat Disord       Date:  2014-09-16       Impact factor: 4.891

9.  Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms.

Authors:  Maria G Cersosimo; Gabriela B Raina; Cristina Pecci; Alejandro Pellene; Cristian R Calandra; Cristiam Gutiérrez; Federico E Micheli; Eduardo E Benarroch
Journal:  J Neurol       Date:  2012-12-21       Impact factor: 4.849

10.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

View more
  4 in total

1.  Perceived stigma and quality of life in Parkinson's disease with additional health conditions.

Authors:  Samia S Islam; Sandy Neargarder; Shraddha B Kinger; Joshua T Fox-Fuller; Robert D Salazar; Alice Cronin-Golomb
Journal:  Gen Psychiatr       Date:  2022-06-22

Review 2.  Parkinson's disease: Are gut microbes involved?

Authors:  Yogesh Bhattarai; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-09-02       Impact factor: 4.052

3.  Quantitative Susceptibility Mapping and Resting State Network Analyses in Parkinsonian Phenotypes-A Systematic Review of the Literature.

Authors:  Esther A Pelzer; Esther Florin; Alfons Schnitzler
Journal:  Front Neural Circuits       Date:  2019-08-06       Impact factor: 3.492

4.  Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson's disease.

Authors:  Yogesh Bhattarai; Jie Si; Meng Pu; Owen A Ross; Pamela J McLean; Lisa Till; William Moor; Madhusudan Grover; Karunya K Kandimalla; Kara G Margolis; Gianrico Farrugia; Purna C Kashyap
Journal:  Gut Microbes       Date:  2021-01-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.